Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ERIC 2020 | CLL treatment: discussing new data from the last 3 years

Arnon Kater • 18 Sep 2020
ERIC 2020
Chronic Lymphocytic Leukemia Leukemia

Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, discusses the importance of being able to debate new research. Over the last 3 years, there has been a large number of clinical trials that have changed the treatment paradigm. Due to each country’s different regulations, it is important to discuss chronic lymphocytic leukemia (CLL) treatment. This interview was recorded during an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Arnon Kater

Epcoritamab monotherapy before chemoimmunotherapy in Richter's transformation: Epcore CLL-1
1:48
Epcoritamab monotherapy before chemoimmunotherapy in Richter's transformation: Epcore CLL-1
Arnon Kater • 6 Dec 2025
Epcoritamab in combination with R-CHOP or lenalidomide for Richter's transformation
1:05
Epcoritamab in combination with R-CHOP or lenalidomide for Richter's transformation
Arnon Kater • 6 Dec 2025
GLOW trial updates: predicting outcomes using genomic aberrations and MRD status
2:28
GLOW trial updates: predicting outcomes using genomic aberrations and MRD status
Arnon Kater • 6 Oct 2023
Overcoming T-cell dysfunction
1:46
Overcoming T-cell dysfunction
Arnon Kater • 6 Oct 2023

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals